David Kliman

452 total citations
28 papers, 255 citations indexed

About

David Kliman is a scholar working on Hematology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, David Kliman has authored 28 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 7 papers in Pediatrics, Perinatology and Child Health and 7 papers in Oncology. Recurrent topics in David Kliman's work include Hematopoietic Stem Cell Transplantation (11 papers), Acute Lymphoblastic Leukemia research (6 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). David Kliman is often cited by papers focused on Hematopoietic Stem Cell Transplantation (11 papers), Acute Lymphoblastic Leukemia research (6 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). David Kliman collaborates with scholars based in Australia, Canada and China. David Kliman's co-authors include David Gottlieb, Emily Blyth, Leighton Clancy, Barbara Withers, Kenneth Micklethwaite, David Bishop, Ming‐Celine Dubosq, Jane Burgess, Peter J. Shaw and Agnes S. M. Yong and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

David Kliman

26 papers receiving 251 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Kliman Australia	6	119	117	71	48	46	28	255
Cécile Pochon France	9	70 0.6×	60 0.5×	74 1.0×	25 0.5×	74 1.6×	35	241
Blanca Herrero Spain	8	64 0.5×	159 1.4×	42 0.6×	49 1.0×	29 0.6×	20	315
Juliana Folloni Fernandes Brazil	6	50 0.4×	34 0.3×	76 1.1×	24 0.5×	48 1.0×	19	211
Xuying Pei China	11	117 1.0×	178 1.5×	138 1.9×	22 0.5×	109 2.4×	26	330
Alexandra Kolenová Slovakia	10	71 0.6×	50 0.4×	136 1.9×	21 0.4×	33 0.7×	40	332
Ben Carpenter United Kingdom	11	160 1.3×	44 0.4×	77 1.1×	48 1.0×	128 2.8×	28	320
Florian Babor Germany	10	58 0.5×	39 0.3×	65 0.9×	23 0.5×	147 3.2×	13	220
S Kojima Japan	7	140 1.2×	106 0.9×	144 2.0×	85 1.8×	31 0.7×	14	341
Jean Hugues Dalle France	6	37 0.3×	58 0.5×	108 1.5×	33 0.7×	20 0.4×	9	198
Lena Rai United Kingdom	7	59 0.5×	52 0.4×	144 2.0×	44 0.9×	40 0.9×	8	273

Countries citing papers authored by David Kliman

Since Specialization

Citations

This map shows the geographic impact of David Kliman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kliman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kliman more than expected).

Fields of papers citing papers by David Kliman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kliman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kliman. The network helps show where David Kliman may publish in the future.

Co-authorship network of co-authors of David Kliman

This figure shows the co-authorship network connecting the top 25 collaborators of David Kliman. A scholar is included among the top collaborators of David Kliman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Kliman. David Kliman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Opat, Stephen, John Hrom, David Kliman, et al.. (2024). BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia.. Journal of Clinical Oncology. 42(16_suppl). TPS7090–TPS7090. 3 indexed citations

Opat, Stephen, John Hrom, David Kliman, et al.. (2024). BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia. Blood. 144(Supplement 1). 1661.1–1661.1. 1 indexed citations

Saner, Nicholas J., David Kliman, Stephen Foulkes, et al.. (2024). Preventing Allogeneic Stem Cell Transplant–Related Cardiovascular Dysfunction: ALLO-Active Trial. Circulation. 151(4). 292–308. 3 indexed citations

Walker, Irwin, Mohamed Elemary, Mahmoud Elsawy, et al.. (2024). A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT). Blood. 144(Supplement 1). 3519–3519.

David, Daniel, et al.. (2024). Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors. Journal of Clinical Oncology. 43(8). 949–959.

Foulkes, Stephen, David Kliman, David W. Dunstan, et al.. (2023). Reduced cardiovascular reserve capacity in long-term allogeneic stem cell transplant survivors. Scientific Reports. 13(1). 2112–2112. 4 indexed citations

Fleming, Shaun, Adam Ivey, Andrew Spencer, et al.. (2023). Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome. Transplantation and Cellular Therapy. 29(7). 454.e1–454.e8. 3 indexed citations

Saner, Nicholas J., David Kliman, Andrew Spencer, et al.. (2022). Preventing the adverse cardiovascular consequences of allogeneic stem cell transplantation with a multi-faceted exercise intervention: the ALLO-Active trial protocol. BMC Cancer. 22(1). 898–898. 3 indexed citations

David, D. F., et al.. (2022). Potential benefits of a virtual, home-based combined exercise and mindfulness training program for HSC transplant survivors: a single-arm pilot study. BMC Sports Science Medicine and Rehabilitation. 14(1). 167–167. 4 indexed citations

10.

Foulkes, Stephen, David Kliman, David W. Dunstan, et al.. (2022). Rapid cardiovascular aging following allogeneic hematopoietic cell transplantation for hematological malignancy. Frontiers in Cardiovascular Medicine. 9. 926064–926064. 5 indexed citations

11.

Kliman, David, Glen Kennedy, Cameron Curley, et al.. (2022). The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. Bone Marrow Transplantation. 57(6). 982–989. 3 indexed citations

12.

Gottlieb, David, Leighton Clancy, Barbara Withers, et al.. (2021). Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant. Clinical & Translational Immunology. 10(3). e1249–e1249. 31 indexed citations

13.

Kliman, David, et al.. (2020). Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma. Bone Marrow Transplantation. 56(5). 1116–1125. 3 indexed citations

14.

Kliman, David, Sushrut Patil, David J. Curtis, et al.. (2020). Important factors in implementation of lineage-specific chimerism analysis for routine use. Bone Marrow Transplantation. 56(4). 946–948. 2 indexed citations

15.

Kliman, David, Ian Nivison‐Smith, David Gottlieb, et al.. (2020). Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation. Biology of Blood and Marrow Transplantation. 26(9). 1711–1718. 12 indexed citations

16.

Kliman, David, Gloria Castellano‐González, Barbara Withers, et al.. (2018). Ultra-Sensitive Droplet Digital PCR for the Assessment of Microchimerism in Cellular Therapies. Biology of Blood and Marrow Transplantation. 24(5). 1069–1078. 36 indexed citations

17.

Kliman, David, Michael J. Barnett, Raewyn Broady, et al.. (2016). Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia. Leukemia & lymphoma. 58(4). 909–915. 3 indexed citations

18.

Kliman, David, Emily Blyth, Vicki Antonenas, et al.. (2016). Infusion of Unrelated-Donor Partially HLA-Matched Cells Results in Detectable Microchimerism in Patients with Acute Myeloid Leukemia: Early Post-Infusion Reactions Are Common but Self-Limiting. Blood. 128(22). 3405–3405. 1 indexed citations

19.

Kliman, David, et al.. (2014). A prospective assessment of methoxyflurane and other analgesic agents during bone marrow biopsy. Pathology. 46. S94–S94. 1 indexed citations

20.

Kliman, David, et al.. (2009). Pediatric Lyme Disease—A School Issue. NASN School Nurse. 24(3). 114–116. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact